Liver Disease Treatment Market: By Treatment Type (Anti-Viral Drugs, Targeted Therapy, Immunosuppressant Drugs, Chemotherapy Drugs, Immunoglobulin, Other Treatment Types), By Disease Type (Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease (NAFLD), Cancer, Genetic Disorders, Others), By Distribution Channel (Hospitals, Ambulatory Surgical Centers, Others), and Geography

Liver Disease Treatment Market size was valued at USD 19,634,9 million in 2023 and is poised to grow at an 6.3% CAGR from 2024 to 2030. Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases. These diseases are commonly caused by infections, genetics, obesity, diabetes, and immune system abnormalities. The rising geriatric population, which is susceptible to various chronic ailments, including liver disease, across the globe is one of the prime factors driving the growth of the liver disease treatment market. The changing dietary patterns and sedentary lifestyles as well as the increasing prevalence of fatty liver disease due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes are favoring the liver disease treatment market growth. Moreover, various technological advancements, such as the development of the bioartificial liver, are providing an impetus to the liver disease treatment market. It utilizes regenerated liver cells to replace liver functions and is widely used for acute liver failure patients. With the increased demand for liver disease treatments, major players have invested capital in researching and developing better drugs, devices, and treatment options.

For example, in December 2020, the American biopharmaceutical corporation Gilead Sciences, Inc. announced the acquisition of MYR GmbH, a German healthcare organization focused on discovering and commercializing therapies for treating chronic liver disease. Gilead declared its intention to buy MYR for approximately USD 1.36 billion in cash. Other such developments and advancements in the liver disease treatment market will make the industry competitive and help it become more efficient, providing the necessary impetus to its growth and lucrative opportunities for the market players. However, considering the high initial investment as well as sum of money needed to purchase the medications and therapies used to treat liver disorders and related conditions are expected to limit the growth of the liver disease treatment market. Moreover, stringent government regulations and guidelines are expected to hamper the growth of the liver disease treatment market. Ongoing trends such as the rapid adoption of antiviral drugs as they are safe and effective, assist in suppressing the hepatitis B virus, and help in reducing the risk of developing cirrhosis and hepatocellular carcinoma, is positively impacting the liver disease treatment market growth.

Liver Disease Treatment Market

• In, January 2023, Takeda and Arrowhead Pharmaceuticals Inc. announced topline results from the Phase 2 SEQUOIA clinical study of investigational Fazirsiran for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD).
• In January 2022, Merck received conditional liver cancer treatment approval for its drug Keytruda based on its second confirmatory study. Keytruda slashed the risk of death by 21% over placebo in hepatocellular carcinoma patients in Asia.